KYTX Insider Trading Activity and SEC Form 4 Filings
KYTX insider trading summary
Over the past 12 months, insiders at Kyverna Therapeutics, Inc. (KYTX) reported 5 open-market purchases worth $5.0M by 5 insiders and 1 sale worth $293K by 1 insider on SEC Form 4. Net insider buying was $4.7M.
Latest KYTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 18, 2025 | Westlake BioPartners Opportunity GP I, LLC | 10% Owner | Buy | $1000K (133,333 @ $7.50) |
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. | 10% Owner | Buy | $1000K (133,333 @ $7.50) |
| Dec 18, 2025 | Westlake BioPartners Fund I, L.P. | 10% Owner | Buy | $1000K (133,333 @ $7.50) |
| Dec 18, 2025 | Beth C Seidenberg | Director | Buy | $1000K (133,333 @ $7.50) |
| Dec 18, 2025 | Westlake BioPartners GP I, LLC | 10% Owner | Buy | $1000K (133,333 @ $7.50) |
| Dec 15, 2025 | Karen Marie Walker | Chief Technology Officer | Sell | $293K (23,998 @ $12.20) |
| Feb 12, 2024 | Vida Ventures, LLC | Insider | Buy | $5.6M (252,553 @ $22.00) |
| Feb 12, 2024 | Bain Capital Life Sciences Fund III, L.P. | Insider | Buy | $9.9M (450,000 @ $22.00) |
| Feb 12, 2024 | Michael P. Rubin | Insider | Buy | $9.9M (450,000 @ $22.00) |
| Feb 12, 2024 | Vida Ventures III, L.P. | Insider | Buy | $5.6M (252,553 @ $22.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.